LUPUS RESEARCH ALLIANCE INC

THE LUPUS RESEARCH ALLIANCE (LRA), THE LARGEST NON-GOVERNMENTAL, PRIVATE FUNDER OF LUPUS RESEARCH WORLDWIDE: FUNDS INNOVATIVE RESEARCH THAT SPANS THE SPECTRUM FROM FOUNDATIONAL TO CLINICAL RESEARCH. FOSTERS DIVERSE SCIENTIFIC TALENT, STIMULATES COLLABORATIONS, AND DRIVES DISCOVERIES TO TRANSFORM TREATMENT WHILE ADVANCING TOWARD A CURE. HAS INVESTED NEARLY $272 MILLION IN LUPUS RESEARCH INCLUDING 620+ RESEARCH GRANTS LRA-FUNDED RESEARCH PAVED THE WAY FOR THE ONLY TWO BIOLOGIC DRUGS CURRENTLY APPROVED FOR LUPUS, AND THE LRA IS INVOLVED IN NUMEROUS ONGOING PHASE 3 TRIALS. FURTHER, LRA RESEARCH INVESTMENTS HAVE CONTRIBUTED TO THE IDENTIFICATION OR FURTHER VALIDATION OF TWO DOZEN DISEASE PATHWAYS IN LUPUS AND HAVE ENABLED THE DISCOVERY, PROOF OF CONCEPT, OR DEVELOPMENT OF MORE THAN A DOZEN DIFFERENT NEW THERAPIES FOR LUPUS. SINCE THE FORMATION OF THE LUPUS CLINICAL INVESTIGATORS NETWORK (LUCIN), LRA HAS DEDICATED $34 MILLION TO BOLSTER LUPUS CLINICAL RESEARCH INFRASTRUCTURE AND QUALITY.THE ORGANIZATION'S RESEARCH COMMITTEE OF THE BOARD OF DIRECTORS AND SCIENTIFIC ADVISORY BOARD INCLUDES TOP SCIENTIFIC EXPERTS, AND KEY LAY MEMBERS OF THE LRA'S BOARD OF DIRECTORS, WHO WORK WITH STAFF TO STRATEGICALLY GUIDE AND DRIVE THE RESEARCH FUNDING AGENDA.IN 2024 ALONE, OVER $12 MILLION WAS AWARDED IN GRANTS FOR 38 HIGHLY INNOVATIVE PROJECTS WITH THE POTENTIAL TO IMPROVE TREATMENT AS WELL AS UNDERSTAND THE CAUSES OF LUPUS AND THUS LEAD TO A CURE. BELOW IS A SUMMARY OF RESEARCH GRANTS AND PROGRAMS FUNDED BY THE LRA IN 2024: 1) 11 LUPUS INNOVATION AWARD GRANTS WERE AWARDED TOTALING ALMOST $4 MILLION OVER TWO YEARS, THIS PROGRAM SUPPORTS PIONEERING, HIGH-RISK, HIGH-REWARD PROJECTS ADDRESSING MAJOR CHALLENGES IN LUPUS RESEARCH. EARLY-STAGE INVESTIGATORS ARE GIVEN SPECIAL CONSIDERATION DURING THE REVIEW PROCESS AND ARE ELIGIBLE FOR A THIRD YEAR OF FUNDING; 2) 6 ADMINISTRATIVE LUPUS RESEARCH SUPPLEMENT GRANTS WERE AWARDED TOTALING $90,000. THIS PROGRAM SUPPORTS PROMISING TRAINEES WHO ARE WORKING WITH LRA-FUNDED RESEARCHERS OR INVESTIGATORS FOCUSED ON AUTOIMMUNITY SUPPORTED BY THE NATIONAL INSTITUTES OF HEALTH (NIH), DEPARTMENT OF DEFENSE (DOD), OR EQUIVALENT GRANTS IN GOOD STANDING. 3) 3 GRANTS TOTALING APPROXIMATELY $1.8 MILLION WERE AWARDED TO RESEARCHERS IN THE CAREER DEVELOPMENT AWARD PROGRAM THAT AIMS TO SUPPORT EARLY CAREER INVESTIGATORS FOR THE PERIOD BETWEEN THE COMPLETION OF POST-DOCTORATE FELLOWSHIP TRAINING AND ESTABLISHMENT AS AN INDEPENDENT INVESTIGATOR. THE PROGRAM PROVIDES UP TO $600,000 OVER FOUR YEARS. 4) 2 POSTDOCTORAL GRANTS FELLOWSHIP GRANTS AWARDED, THIS GRANT IS DESIGNED TO FUND PROMISING RESEARCH FELLOWS AND PROVIDES THEM WITH UP TO $170,000 OVER TWO YEARS TO SUPPORT THE GENERATION OF DATA, UNIQUE RESEARCH IDEAS AND PROGRESS TO TRANSITION TO AN INDEPENDENT RESEARCH ROLES FOCUSED ON LUPUS RESEARCH. 5) 5 TRANSLATIONAL BRIDGE AWARDS FUNDED TOTALING APPROXIMATELY $2.2 MILLION. THIS PROGRAM PROVIDES UP TO $450,000 OVER TWO YEARS, WITH A GOAL TO BRIDGE THE GAP BETWEEN POST-DISCOVERY AND PRE-COMMERCIAL DEVELOPMENT WITH AN AIM TO ACCELERATE THE PACE AT WHICH PROMISING LRA-FUNDED FOUNDATIONAL RESEARCH DISCOVERIES ARE TRANSLATED INTO CLINICAL EVALUATION AND TRANSITIONED TO A VIABLE PRODUCT THAT WILL IMPACT PATIENTS DIRECTLY. 6) 11 TARGETED RESEARCH PROGRAM ON ENGINEERED CELL THERAPIES FOR LUPUS GRANTS TOTALING OVER $4 MILLION. THIS PROGRAM ADVANCES THE DEVELOPMENT OF NEXT GENERATION ENGINEERED CELL THERAPIES WITH A CLEAR AND DIRECT RELEVANCE TO PEOPLE WITH LUPUS.7) THE LUPUS INSIGHT PRIZE WAS AWARDED $200,000. THIS AWARD RECOGNIZED TWO LEADING RESEARCHERS WHO HAVE MADE A MAJOR CONTRIBUTION RELEVANT TO LUPUS, AS PART THE LRA'S COMMITMENT TO COLLABORATION, THE LRA WORKS WITH A VARIETY OF PARTNERS ACROSS SECTORS AIMED AT ACCELERATING RESEARCH DISCOVERIES, LEVERAGING RESOURCES, AND EXPEDITING THE DRUG DEVELOPMENT PROCESS TO IMPROVE THE QUALITY OF LIFE OF PEOPLE LIVING WITH LUPUS BRINGING TOGETHER THE KEY PLAYERS IN THE FIGHT AGAINST LUPUS -- OUR GRANTEES, SCIENTIFIC ADVISORS, CLINICIANS, THE BIOPHARMACEUTICAL INDUSTRY, THE U.S. GOVERNMENT, AND PEOPLE LIVING WITH LUPUS. THE LRA'S ROBUST FUNDING MODEL SUPPORTS PROMISING RESEARCH EFFORTS WITH THE GOAL OF IMPROVING THE LIVES OF PEOPLE WITH LUPUS SOON. THROUGH COMPETITIVE PEER-REVIEW PROCESS PROJECTS BY THE LRA AIM TO TRANSLATE RESULTS FROM THE RESEARCH BENCH TO THE BEDSIDE AS QUICKLY AS POSSIBLE. BECAUSE THE LUPUS RESEARCH ALLIANCE'S BOARD OF DIRECTORS FUNDS THE ADMINISTRATIVE AND FUNDRAISING EXPENSES, 100% OF ALL OTHER CONTRIBUTIONS GOES TO SUPPORT THE LRA'S LUPUS RESEARCH PROGRAMS.

THE LUPUS RESEARCH ALLIANCE (LRA) HAS MADE SIGNIFICANT STRIDES IN ADVANCING ITS SCIENTIFIC MISSION THROUGH STRATEGIC PLANNING, PROGRAM EXPANSION AND OPERATIONAL IMPROVEMENTS.IN 2024, THE LRA SUCCESSFULLY DEVELOPED AND IMPLEMENTED THE FIRST-YEAR GOALS OF ITS 20242028 RESEARCH STRATEGY. IN ALIGNMENT WITH THE UPDATED RESEARCH STRATEGY, LRA LAUNCHED SEVERAL INNOVATIVE, PATIENT-CENTRIC RESEARCH INITIATIVES, INCLUDING THE TRANSLATIONAL BRIDGE AWARD, THE TARGETED RESEARCH PROGRAM ON ENGINEERED CELL THERAPIES, THE RENEWED CYCLE OF THE COMMON MECHANISMS IN AUTOIMMUNE DISEASES PROGRAM, AND THE MECHANISTIC CLINICAL STUDIES AWARD. ADDITIONALLY, THE ORGANIZATION BEGAN DEVELOPING A LUPUS BIOMARKERS STRATEGY AND INITIATED THE DEVELOPMENT OF A COMPREHENSIVE DATA STRATEGY, SCHEDULED FOR COMPLETION IN 2025.LRA'S CURRENT GRANT PROGRAMS, INCLUDING THE GLOBAL TEAM SCIENCE AWARD (GTSA), CAREER DEVELOPMENT AWARD, POST DOCTORAL AWARD, AND LUPUS INNOVATION AWARD --WERE EXPANDED AND OPTIMIZED THROUGH ACTIVE STAFF OVERSIGHT AND STRATEGIC COLLABORATIONS. THIS INCLUDED LAUNCHING A REQUEST FOR APPLICATIONS IN A COLLABORATIVE PROGRAM ACROSS THE GTSA AND CONTINUING THE ADMINISTRATIVE SUPPLEMENT TRAINING PROGRAM.TO RAISE THE VISIBILITY OF ITS RESEARCH PROGRAMS, LRA SUBMITTED MULTIPLE ABSTRACTS TO INTERNATIONAL SCIENTIFIC MEETINGS, SEVERAL WERE ACCEPTED AND WILL BE PRESENTED IN 2025. THE ORGANIZATION ALSO HOSTED A SUCCESSFUL AND ENGAGING ANNUAL INVESTIGATOR'S AND PROGRAM SPECIFIC MEETINGS: FORUM FOR DISCOVERY, ALLIANCE OF GTSA AND OTHER PROGRAM-SPECIFIC RESEARCH MEETINGS IN NOVEMBER OF 2024. OPERATIONAL IMPROVEMENTS INCLUDED THE SELECTION AND IMPLEMENTATION OF A NEW GRANT MANAGEMENT SYSTEM, THE RECRUITMENT AND ONBOARDING OF TWO STAFF SCIENTISTS AND A LUPUS ABC ADMINISTRATOR, AND THE STRENGTHENING OF THE RESEARCH TEAM THROUGH TARGETED TEAM-BUILDING AND PROFESSIONAL DEVELOPMENT EFFORTS. LUPUS ABC HAS BEEN SUCCESSFULLY ESTABLISHED AS A MODEL PUBLIC-PRIVATE PARTNERSHIP IN THE REGULATORY SPACE, DEMONSTRATING LEADERSHIP AND INNOVATION IN ADVANCING LUPUS RESEARCH AND EXPERIENCED SUBSTANTIAL GROWTH IN MEMBERSHIP DURING 2024. THE INITIATIVE SECURED ACTIVE PARTICIPATION FROM THE FDA'S CENTER FOR BIOLOGICS EVALUATION AND RESEARCH, REINFORCING ITS CREDIBILITY AND COLLABORATIVE STRENGTH. A MAJOR MILESTONE WAS THE FDA'S ACKNOWLEDGMENT OF CLASI 70 AS A PRIMARY EFFICACY ENDPOINT IN CUTANEOUS LUPUS CLINICAL TRIALS, MARKING A SIGNIFICANT ADVANCEMENT IN CLINICAL OUTCOME MEASUREMENT. ADDITIONALLY, LUPUS ABC CONVENED A DEDICATED PATIENT-REPORTED OUTCOMES (PRO) MEETING TO FURTHER INTEGRATE PATIENT PERSPECTIVES INTO RESEARCH AND REGULATORY STRATEGIES. LUPUS NEXUS COMPLETED ITS INFRASTRUCTURE BUILD AND OFFICIALLY LAUNCHED TO BOTH RESEARCH AND PATIENT COMMUNITIES. IT FINALIZED FOUNDATIONAL ANALYSIS PLANS, SELECTED KEY VENDORS, AND RECRUITED 200 PARTICIPANTS. ADDITIONALLY, 10 NEW CLINICAL SITES WERE ACTIVATED THROUGH LUCIN (SEE BELOW), AND A SUSTAINABLE FINANCIAL MODEL WITH A DEFINED MEMBERSHIP FEE STRUCTURE WAS ESTABLISHED. LUPUS THERAPEUTICS, LLC :THE LRA FOUNDED LUPUS THERAPEUTICS, LLC (LT) AS THE CLINICAL RESEARCH AFFILIATE OF THE LRA IN 2018. WITH THIS ADDITION, THE LRA IS THE ONLY ORGANIZATION LEADING LUPUS RESEARCH ACROSS THE CONTINUUM FROM ACCELERATING BASIC DISCOVERIES IN THE LAB THROUGH CLINICAL EVALUATION OF NEW THERAPIES. MANY OF THE BASIC RESEARCH BREAKTHROUGHS SUPPORTED BY THE LRA HAVE HELPED UNRAVEL THE COMPLEXITIES OF LUPUS AND ENABLED THE DEVELOPMENT OF POTENTIAL TREATMENTS AND DIAGNOSTICS NOW IN CLINICAL STUDIES. LT IS ACTIVELY SUPPORTING SEVERAL CLINICAL STUDIES FOR NEW THERAPIES THROUGH THE LUPUS CLINICAL INVESTIGATORS NETWORK (LUCIN). LT OVERSEES LUCIN, A NORTH AMERICA-BASED LUPUS CLINICAL TRIALS NETWORK OF 60+ PREMIER RESEARCH MEDICAL CENTERS. THE LRA PROVIDED OVER $2.6 MILLION IN GRANTS IN 2024 TO CONTINUE FUNDING TOP ACADEMIC CENTERS TO FOSTER ROBUST, HIGH QUALITY CLINICAL TRIAL CONDUCT WITH PARTICIPATION ACROSS NORTH AMERICA.LT ALSO OFFERS EXPERTISE COMBINED WITH THAT OF 250+ LUCIN PROVIDERS AND THE LRA TO SUPPORT ACADEMIC, NONPROFIT AND BIOTECH AND PHARMACEUTICAL ORGANIZATIONS TO PLAN, INITIATE AND MANAGE CLINICAL RESEARCH. THIS OCCURS THROUGH DIVERSE ADVISORY SERVICES AND DIRECT CLINICAL OPERATIONS SUPPORT. AN ANNUAL LUCIN COMMUNITY MEETING IS HELD TO BRING TOGETHER ALL OF THE PARTNERS IN CLINICAL RESEARCH TO HIGHLIGHT RECENT ADVANCEMENTS, BOLSTER UNDERSTANDING, ADDRESS CURRENT CHALLENGES IN CLINICAL RESEARCH AND ENCOURAGE COLLABORATION FOR SUCCESSFUL DEVELOPMENT OF NEW TREATMENT APPROACHES.IN ADDITION, LT HAS EXPANDED THE FIRST PEER-TO-PEER CLINICAL TRIALS EDUCATION PROGRAM, PATIENT ADVOCATES FOR LUPUS STUDIES OR PALS TO INCLUDE TRIAL BUDDY SUPPORT DURING PARTICIPATION IN CLINICAL TRIALS. PALS AIMS TO IMPROVE CLINICAL RESEARCH AWARENESS, KNOWLEDGE AND ENROLLMENT, WITH A SPECIFIC FOCUS ON MAKING SURE POPULATIONS AT GREATEST RISK FOR LUPUS ARE WELL REPRESENTED IN STUDIES. LT ALSO SUPPORTS OTHER PATIENT ENGAGEMENT ACTIVITIES SUCH AS PATIENT ADVISORY BOARDS, PATIENT VISITS AND PATIENT PROTOCOL REVIEW COMMITTEES TO ENSURE THAT INDIVIDUALS IMPACTED BY LUPUS HAVE A VOICE IN THE TREATMENT DEVELOPMENT PROCESS. FINALLY, LT EFFORTS SUPPORT VARIOUS EDUCATION OFFERINGS FOR PROVIDERS AND PATIENTS, AND COMMUNITY-BASED OUTREACH TO ENSURE REPRESENTATIVE PARTICIPATION OF THE ENTIRE LUPUS COMMUNITY IN CLINICAL RESEARCH.